Clinical trial · Interventional
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
A Phase II Study of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
NCT00513786CI-TRIAL-00087814completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Purpose of this study is to determine the effectiveness of the drug combination carboplatin, paclitaxel, and bevacizumab(Avastin) in patients with advanced stage endometrial carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bevacizumab | Drug | Bevacizumab | ALIAS |
| Carboplatin | Drug | Carboplatin | ALIAS |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- carboplatin/paclitaxel with bevacizumab
- description
- A regimen of Carboplatin and paclitaxel combined with bevacizumab given every 21 days in patients with advanced stage endometrial cancer for a maximum of 6 cycles.
- interventionNames
- Drug: Carboplatin
- Drug: Paclitaxel
- Drug: bevacizumab
Primary outcomes (1)
- measure
- Evaluate Patients With Progression Free Survival (PFS)
- timeFrame
- up to 57 months
- description
- Progressive Disease (PD) is defined at least a 20% increase in the sum of the longest dimension of target lesions, taking as reference the smallest sum of the longest dimension recorded since the treatment start or the appearance of one or more new lesions.
Secondary outcomes (3)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced Stage Endometrial Cancer (Stage 3 or 4) * Any Histology including clear cell, and serous papillary carcinomas * surgery must have had hysterectomy and bilateral salpingo-oophorectomy * chemotherapy initiated 12 weeks after surgery * sign informed consent * Adequate End-organ function * GOG (Gynecologic Oncology Group)Performance Status 0,1,2 * Patients must be 18 years or older * Patients may have received radiation for the treatment of endometrial cancer. * Patients may have measurable or non-measurable disease. Exclusion Criteria: * Patient with concomitant malignancy other than non-melanoma skin cancer * Patients with prior malignancy who have been disease free for 5 years. * Patients with serious uncontrolled infection, angina or serious peripheral neuropathy. * Patients whose circumstances will not permit study completion or adequate follow up * Patients who have received prior cytotoxic chemotherapy for treatment of endometrial cancer including chemotherapy used for radiation sensitization.
References
Publications (0)
Data not yet available
No reference posted for this study.